Journal
DALTON TRANSACTIONS
Volume 40, Issue 21, Pages 5781-5792Publisher
ROYAL SOC CHEMISTRY
DOI: 10.1039/c0dt01785j
Keywords
-
Categories
Funding
- Fundacao para a Ciencia e Tecnologia (FCT) [SFRH/BPD/29564/2006, PTDC/QUI/66813/2006]
- COST Action [D39]
- FEDER
Ask authors/readers for more resources
A series of four Pt(II) complexes anchored by bidentate or tridentate pyrazolyl-alkylamine chelators bearing different substituents at the azolyl rings has been prepared with the aim to assess their interest in the design of novel anticancer drugs. All complexes have been fully characterized by classical analytical methods and three of them were characterized also by X-ray diffraction analysis. Their solution behavior, together with lipophilicity measurements, cell uptake, antiproliferative properties, DNA interaction have been evaluated. Albeit all the complexes were less active than cisplatin on ovarian carcinoma A2780 cell line, greatly retained their activity in the cisplatin-resistant A2780cisR cell line and presented a lower resistance factor compared to cisplatin. Moreover, the Pt(II) complexes under investigation were less prone to undergo deactivation by glutathione, believed to be the major cellular target of cisplatin that inactivates the drug by binding to it irreversibly.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available